Evidence map›Paper›PMID 40916029›Full record

ArticleJournal of cancer survivorship : research and practice2025

Clinical and social determinants of survivorship clinic attendance in head and neck cancer.

Maryanna S Owoc, Katie M Carlson, Marci Lee Nilsen, Yvonne M Mowery, Kevin J Contrera, Jennifer Hetrick, Nosayaba Osazuwa-Peters, Dan P Zandberg, Sandra Stinnett, Jonas T Johnson and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cancer survivorship : research and practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Maryanna S Owoc *Department of Otolaryngology - Head and Neck Surgery, University of Pittsburgh Medical Center, 203 Lothrop St # 500, Pittsburgh, PA, 15213, USA.
Katie M Carlson *Department of Otolaryngology - Head and Neck Surgery, University of Pittsburgh Medical Center, 203 Lothrop St # 500, Pittsburgh, PA, 15213, USA.
Marci Lee NilsenDepartment of Otolaryngology - Head and Neck Surgery, University of Pittsburgh Medical Center, 203 Lothrop St # 500, Pittsburgh, PA, 15213, USA.
Yvonne M MoweryUPMC Hillman Cancer Center, 5115 Centre Ave, Pittsburgh, PA, 15232, USA.
Kevin J ContreraDepartment of Otolaryngology - Head and Neck Surgery, University of Pittsburgh Medical Center, 203 Lothrop St # 500, Pittsburgh, PA, 15213, USA.
Jennifer HetrickDepartment of Otolaryngology - Head and Neck Surgery, University of Pittsburgh Medical Center, 203 Lothrop St # 500, Pittsburgh, PA, 15213, USA.
Nosayaba Osazuwa-PetersDepartment of Head and Neck Surgery and Communication Sciences, Duke University School of Medicine, Davison Building, 40 Duke Medicine Cir Box 3805, Durham, NC, 27710, USA.
Dan P ZandbergUPMC Hillman Cancer Center, 5115 Centre Ave, Pittsburgh, PA, 15232, USA.
Sandra StinnettDepartment of Otolaryngology - Head and Neck Surgery, University of Pittsburgh Medical Center, 203 Lothrop St # 500, Pittsburgh, PA, 15213, USA.
Jonas T JohnsonDepartment of Otolaryngology - Head and Neck Surgery, University of Pittsburgh Medical Center, 203 Lothrop St # 500, Pittsburgh, PA, 15213, USA.
Angela L MazulDepartment of Otolaryngology - Head and Neck Surgery, University of Pittsburgh Medical Center, 203 Lothrop St # 500, Pittsburgh, PA, 15213, USA. angela.mazul@pitt.edu.

Funding

VECTOR CORE FACILITYP30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI JOHN C. BYRD · 1988 to 2026
$158.0M
WILD TYPE P53-BASED ADJUVANT IMMUNOTHERAPY FOR SCCHNP50CA097190 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Greg M. Delgoffe · 2004 to 2026
$49.6M
HPV, HIV and Oral Microbiota Interplay in Nigerian Youth (HOMINY)R01DE032216 · NIDCR · UNIVERSITY OF PENNSYLVANIA · PI MODUPE COKER, Nosayaba Osazuwa-Peters · 2022 to 2026
$4.5M
Radiation-Induced Fibrosis and Co-occurring Adverse Treatment-Related Effects in Head and Neck Cancer SurvivorsR37CA279210 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI MARCI LEE NILSEN · 2023 to 2026
$2.5M
Suicide risk detection and mitigation in patients with head and neck cancerK01DE030916 · NIDCR · DUKE UNIVERSITY · PI OSAZUWA-PETERS, NOSAYABA · 2021 to 2025
$821k
Employing Novel Primary Mouse Models of Head and Neck Cancer to Overcome Chemoradiation ResistanceK08DE029887 · NIDCR · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI MOWERY, YVONNE MARIE · 2020 to 2024
$804k
Long-term Opioid Therapy, Depression and Suicide Mortality Risk in Patients with Head and Neck CancerR21DE032531 · NIDCR · DUKE UNIVERSITY · PI OSAZUWA-PETERS, NOSAYABA · 2022 to 2022
$448k
National Institutes of Health grants Head and Neck Specialized Program of Research Excellence (SPORE) P50 CA097190-17NCI NIH HHS P30 CA047904NCI NIH HHS P30CA047904NCI NIH HHS P50 CA097190NCI NIH HHS R37 CA279210NIDCR NIH HHS K01 DE030916NIDCR NIH HHS K08 DE029887NIDCR NIH HHS R01 DE032216NIDCR NIH HHS R21 DE032531
6 · The paper itself

Abstract

purposeDespite its importance, little is known about the patterns and predictors of Survivorship Clinic attendance in head and neck cancer (HNC). We sought to determine the cumulative incidence of Survivorship Clinic attendance stratified by demographic, clinical, and socioeconomic factors, and to identify factors independently associated with attendance.

methodsOur analysis population consisted of 2,252 patients diagnosed with primary HNC and seen at our institution's HNC Survivorship Clinic after completing treatment from 2016-2021. Factors associated with increased likelihood of attending the Survivorship Clinic post-treatment, within five years of diagnosis, were identified using Cox proportional hazards regression.

resultsThe overall cumulative incidence of Survivorship Clinic attendance reached 47.5% (95% confidence interval [CI]: 44.3-50.5%). Greater distance from clinic ((30-60 miles] hazard ratio [HR]: 0.58, 95% CI: 0.44-0.76, and > 60 miles HR: 0.46, 95% CI: 0.34-0.62) was independently associated with decreased likelihood of attendance. Factors independently associated with increased likelihood of attendance were stage III (HR: 1.47, 95% CI: 1.11-1.95) or IV (HR: 1.54, 95% CI: 1.15-2.05) cancer and treatment with radiotherapy (HR: 2.78, 95% CI: 2.12-3.64).

conclusionsLess than half of our cohort attended the Survivorship Clinic post-treatment, within the first five years of diagnosis. Clinical factors, including disease stage and treatment modality, and social determinants, including distance from the clinic, were independently associated with Survivorship Clinic attendance. IMPLICATIONS FOR CANCER SURVIVORS: These findings underscore the need for targeted interventions to increase access to survivorship care in HNC.

Indexed as

Access to survivorship careCancer survivorshipHead and neck cancerSocial determinants of health

Identifiers

PMID40916029
PMCPMC12875402

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.